CtrlK
EW
NYSE
Health Care
$95.18
USD
+$0.81 (+0.86%)
At close: Jul 6, 2026, 4:00 PM EDT
Market Cap:
$54.33B
Volume:
3.9M
Previous Close
$94.37
Day Range
$92.72 - $95.57
52 Week Range
$72.30 - $95.57
Average Volume (10 Days)
5.1M
P/E Ratio
50.61
Dividend Yield
—
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 16,000 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
CEO
Mr. Bernard Zovighian
Headquaters
Irvine, CALIFORNIA, US
Founded
2000
Employees
16,000
The SURVIV trial found Edwards Lifesciences' transcatheter mitral valve-in-valve procedure significantly reduced death or disabling stroke within one year compared to repeat open-heart surgery in select high-risk patients with failing mitral bioprostheses. The primary benefit came from fewer early complications, though longer-term durability remains under investigation.
0
0
Edwards Lifesciences-sponsored SURVIV trial showed patients with failed mitral valves who received a transcatheter valve-in-valve procedure using the company's device had significantly lower death or stroke rates at one year compared to those who underwent traditional redo surgery. However, surgical patients showed better valve performance and the trial was limited to a specific high-risk population in Brazil, with long-term durability still under evaluation.
0
0
SYK
Stryker Corp
$324.73
-0.6%
